Serotonin syndrome (warning)
The potentially fatal reaction from serotonin excess that means 5-HTP must never be combined with antidepressants
Definition
Serotonin syndrome is a potentially life-threatening adverse reaction caused by excessive serotonin (5-HT) activity in the central and peripheral nervous system. It arises when substances that raise serotonin are combined—SSRI/SNRI antidepressants, MAOIs, triptans, tramadol, lithium, and precursors such as 5-HTP or tryptophan. It presents as a triad of altered mental status (agitation, confusion), autonomic hyperactivity (fever, tachycardia, sweating), and neuromuscular abnormalities (clonus, tremor, rigidity). It can escalate from mild to fatal within hours. This is why 5-HTP must never be combined with serotonergic drugs without medical supervision.
Detailed explanation
Serotonin syndrome results from overstimulation of serotonin receptors, particularly the 5-HT2A subtype. Diagnosis is clinical: the Hunter criteria (2003) offer higher sensitivity and specificity than the older Sternbach criteria and require spontaneous, inducible, or ocular clonus alongside agitation, diaphoresis, tremor, hyperreflexia, or hyperthermia in a patient exposed to a serotonergic agent.
The risk mechanism with 5-HTP is direct: as the immediate precursor of serotonin (5-HTP → 5-HT via AADC decarboxylase), it increases neurotransmitter synthesis. Combined with an SSRI (which blocks reuptake) or an MAOI (which blocks degradation), serotonin accumulates to dangerous levels. Combination with an MAOI carries the greatest risk.
Management includes immediate withdrawal of the causative agent, supportive care (hydration, temperature control), benzodiazepines for agitation, and—in moderate-to-severe cases—cyproheptadine as a 5-HT2A antagonist. Prevention is decisive: never overlap serotonergic precursors with antidepressants without medical evaluation and an adequate washout period.
Scientific sources
Related terms
Interested in related treatments?
Generate My Protocol